Clinical Trial Findings & Response Rates
In pivotal FDA clinical trials, patients with Treatment-Resistant Depression (TRD) who added SPRAVATO® to an oral antidepressant demonstrated statistically significant improvement compared to those who took an oral antidepressant plus a placebo spray.
Experienced 50%+ reduction in depressive symptoms
Many report initial symptom relief within hours
Lower risk of depressive relapse during maintenance
Why SPRAVATO® Works Differently Than Oral Meds
Most standard antidepressants target monoamines (serotonin, norepinephrine, dopamine). SPRAVATO® uniquely targets glutamate, the brain's most abundant neurotransmitter. By boosting synaptogenesis and synapse connectivity in prefrontal circuits, SPRAVATO® repairs neural pathways damaged by chronic stress and depression.
Frequently Asked Questions
What is the success rate of SPRAVATO® esketamine nasal spray?
Clinical trials demonstrate that approximately 70% of patients with treatment-resistant depression experience significant symptom reduction or remission when adding SPRAVATO® to an oral antidepressant.
How fast does SPRAVATO® start working?
Unlike traditional oral antidepressants that take 4 to 6 weeks, many SPRAVATO® patients report noticeable depressive relief within 24 to 48 hours following their initial doses.
Is SPRAVATO® covered by health insurance?
Yes. SPRAVATO® is FDA-approved for Treatment-Resistant Depression (TRD) and Major Depressive Disorder with suicidal ideation, and is covered by Medicare and most commercial insurance plans (BCBS, Aetna, Cigna, UHC).
Why is two hours of post-dose observation required?
FDA REMS safety guidelines require patients to remain in a certified healthcare setting for 2 hours post-dose to monitor for transient blood pressure changes or mild sedation.
Related Resources
See If SPRAVATO® Is Right For You
Our clinical team in Coral Springs, FL will verify your insurance and guide you through every step of SPRAVATO® treatment.